Committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases, Biocon has effectively utilized India’s cost advantage to become the largest Biotechnology Company in the country. Biocon has successfully emerged into a global biopharma enterprise with customers from over 75 countries.
As a fully integrated biopharma company with its key innovations: indigenous recombinant human insulin based on proprietary fermentation technology, INSUGEN®, insulin analogue Glargine, BASALOG® and India’s first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer & INSUPen® a next generation affordable insulin delivery device, Biocon now aspires to become a US $ 1 billion company by FY 18.
Leveraging India’s globally competitive cost base and exceptional scientific talent, Reasearch & Development program is being advanced along with providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene.
- Auto-immune diseases
|Traded as||BSE: 532523; NSE: BIOCON|
|Headquarters||Bangalore, Karnataka, India|
|Key people||Kiran Mazumdar-Shaw, (Chairman & MD)|
|Revenue||₹22.41 billion (US$360 million) (2014–15)|
|Net income||₹3.61 billion (US$57 million) (2014–15)|
|Number of employees||5,585 (Mar 2011)|